{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:24Z","timestamp":1790679204682,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012317","name":"UCL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bbadis.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T19:24:20Z","timestamp":1563218660000},"page":"2726-2735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients"],"prefix":"10.1016","volume":"1865","author":[{"given":"Wendy E.","family":"Heywood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Doykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Spiewak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hallqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2019.07.005_bb0005","doi-asserted-by":"crossref","unstructured":"I.Y. Desnick R, Eng C, \u03b1-Galactosidase A Deficiency: Fabry Disease, McGraw-Hill, New York, 2001.","DOI":"10.1006\/rwgn.2001.0443"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease","volume":"41","author":"Alharbi","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0005-2736(92)90096-5","article-title":"Effects of fatty acid alpha-hydroxylation on glycosphingolipid properties in phosphatidylcholine bilayers","volume":"1103","author":"Singh","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0040","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/cr2002917","article-title":"Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics","volume":"111","author":"Merrill","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0045","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a004788","article-title":"Glycosphingolipid functions","volume":"3","author":"Lingwood","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0055","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2016-0027","article-title":"Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion","volume":"2","author":"Kamani","year":"2016","journal-title":"Future Sci OA"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ymgme.2015.12.006","article-title":"Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders","volume":"117","author":"Ferraz","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0065","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0075","series-title":"Diagnosis of Sphingolipidoses: A New Simultaneous Measurement of Lysosphingolipids by LC-MS\/MS, Clinical Chemistry and Laboratory Medicine\u202f: CCLM\/FESCC","first-page":"403","volume":"55","author":"Polo","year":"2017"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0080","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS\/MS in urine of Fabry disease patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0085","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.analchem.5b04227","article-title":"Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson disease","volume":"88","author":"Boutin","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0090","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0100","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/elps.201700461","article-title":"Modern separation techniques coupled to high performance mass spectrometry for glycolipid analysis","volume":"39","author":"Sarbu","year":"2018","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jssc.201701010","article-title":"Mobile phase effects on the retention on polar columns with special attention to the dual hydrophilic interaction-reversed-phase liquid chromatography mechanism, a review","volume":"41","author":"Jandera","year":"2018","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0110","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1007\/s00216-016-9716-4","article-title":"Evaluation of coverage, retention patterns, and selectivity of seven liquid chromatographic methods for metabolomics","volume":"408","author":"Wernisch","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0115","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2019.07.005_bb0125","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2019.07.005_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci. Lett."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443919302285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443919302285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:49:07Z","timestamp":1760417347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443919302285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0925443919302285"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2019.07.005","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}